Skip to main content

Table 3 Comparison between the non-high-dose and high-dose groups of patients after randomly matched analysis by using Greedy method

From: Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis

Characteristic Non-high-dose Group (n = 104) High-dose Group (n = 104) P-value
Age (years) 65.6 ± 11.8 65.5 ± 13.9 0.258
Female gender, n (%) 24(23.1) 39(37.5) 0.024*
Creatinine(mg/dl) 2.4 ± 2.3 2.8 ± 2.9 0.010*
Hb (g/L) 88.9 ± 25.2 89.1 ± 27.6 0.386
Platelet(× 109/L) 191.5 ± 88.8 198.9 ± 106.3 0.113
Use of NSAIDs, n (%) 9(8.7) 11(10.6) 0.638
Use of aspirin, n (%) 15(14.4) 18(17.3) 0.569
Use of clopidogrel, n (%) 11(10.6) 13(12.5) 0.664
Use of wafarin, n (%) 6(5.8) 10(9.6) 0.298
Shock at presentation 52(50.0) 65(62.5) 0.069
Coexisting illness, n (%)    
CKDIII, IV/V 40/14 (38.5/13.5) 40/15(38.5/14.4) 0.978
COPD 7(6.7) 6 (5.8) 0.775
CAD 19(18.3) 28(26.9) 0.136
DM 34(32.7) 39(37.5) 0.468
CVA 21(20.2) 23(22.1) 0.734
Liver Cirrhosis 20(19.2) 14(13.5) 0.261
Rockall score 6.4 ± 1.4 6.4 ± 1.4 1.000
Time to endoscope (h) 16.4 ± 20.3 16.9 ± 19.8 0.482
PRBC BT(mL) 1252.4 ± 1272.1 2156.3 ± 2117.1 0.007
Ulcer size (cm) 1.0 ± 0.6 0.9 ± 0.6 0.901
Multiple ulcers, n (%) 29(27.9) 38(36.5) 0.182
Forrest classification Ia/Ib/IIa/IIb/IIc/III 2/70/6/26/0/0 3/70/6/25/0/0 0.974
Re-bleeding, n (%) 14 (13.5) 34 (32.7) 0.001*
Surgery, n (%) 2(1.9) 1(1.0) 0.561
Hospital stay (days) 13.9 ± 22.3 17.9 ± 15.3 0.641
Mortality, n (%) 10(9.6) 16(15.4) 0.403
Bleeding related/Other causes 4/6 8/8  
  1. Abbreviation: Hb, hemoglobin; NSAID, nonsteriodal anti-inflammatory drug; CKD, chronic kidney disease; PPI, proton-pump inhibitor; DM, diabetes mellitus type 2; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CVA, cerebrovascular accident; BT, blood transfusion. * p < 0.05